Drugs · acquisition-cost intelligence
gabapentin
· ingredient gabapentinGabapentinoids· GABAPENTIN 250 mg/5mL; GABAPENTIN 50 mg/mL
What this is. Acquisition-cost intelligence for pharmacy & clinic buyers — the historical trend, generic-equivalent costs, and Part D posture. NADAC is a pharmacy acquisition cost (the national average pharmacies pay), not a retail or cash price — for consumer cash prices use GoodRx/your plan.
Acquisition benchmark · NADAC per ML
$0.08386
NADAC — pharmacy acquisition cost, not a retail/cash price
Acquisition-cost history
Weekly NADAC per ML — the trend nobody else shows. 7 weeks.
2025-12-172026-05-20
Same-ingredient options by acquisition cost
Other gabapentin products, cheapest acquisition cost first. Per ML — confirm strength/form equivalence before switching.
| Product | NADAC / ML | vs this |
|---|---|---|
| gabapentin | $0.03246 | −$0.05140 |
| gabapentin | $0.06824 | −$0.01560 |
| Gabapentin | $0.09799 | +$0.01410 |
| gabapentin | $1.16 | +$1.08 |
| GABARONE | $8.52 | +$8.44 |
| Gralise | $10.20 | +$10.11 |
| Horizant | $17.92 | +$17.83 |
Medicare Part D coverage · CY2026
On 328 plan formularies · typical tier 3
Prior auth 0% · Step therapy 0% · Quantity limit 88% of formularies
Sources: CMS NADAC (pharmacy acquisition cost), FDA NDC + RxNorm (identity), RxClass (therapeutic class), CMS Medicare Part D formulary (coverage). Observed reference data for professional buyers — not a retail/cash price, not pricing or medical advice. Verify before purchasing or substituting.